Hungarian drug company Richter and US peer Forest Laboratories announced on Tuesday that top-line results from Phase II clinical testing of its analgesic radiprodil failed to show statistically significant or clinically meaningful reductions in mean daily pain scores compared to placebos for any of the dosages analyzed.
Radiprodil is a drug aimed at treatment of chronic neuropathic pain, including that stemming from diabetes.
The companies will review the complete study database over the coming weeks to determine the appropriate next steps regarding the development of radiprodil, the announcement said.
Richter and Forest Laboratories have formed a strategic partnership to develop pharmaceuticals including the antipsychotic drug cariprazine, Phase IIb clinical trials for which have been positive. (MTI-Econews)